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Sinry 1The cinical formulation of the anti-tumour agent Taxol involves the use of a mixture of ethanol
and Cremophor EL. Gel eectrophoresis and density-gradient ultracentrifigation were used to detect effects of
Taxol infusions on serum poproteins. Use of the Cremophor vehicle results in a decrease in the eectro-
phoretic mobity of serm hpoproteis along with the appearance of a lpoprotein dissociation product. These
effects persist during a 24 h infusion and for at kast 1.5 h afterwards, and can be reproduced in vitro using
purified high-density lpeprotein (HDL) or low-density lipoprotein (LDL). In control serum, Taxol binds to
albumin >HDL, but after serm is exposed to Cremophor EL in vitro or in viwo substantial binding of Taxol
to the lipoprotein dissociation product(s) was observed The latter could represent an important factor in taxol
biodistribution.
Taxol is a new anti-tumour agent that shows activity against
previously intractable solid tumours in man (Wiernik et al.,
1987; Slichenmyer & von Hoff, 1991). For clinical use, the
drug is solubilised by a mixture of Cremophor and ethanol.
Cremophor is also used in the formulation of the immuno-
suppressive drug cyclosporin, as well as hydrophobic agents
used in the selective photosensitisation of malignant tissues
(Morgan et al., 1988). Lipoprotein alterations accompanying
administration of miconazole formulated with Cremophor
were reported in 1977 by Bagnarello et al. A recent report
indicated that exposure to Cremophor alters the buoyant
density of HDL (Kongshaug et al., 1991). We have extended
this observation and found that exposure to Cremophor can
change the distribution of several fluorescent probes for
albumin versus lipoproteins, and also modify the electro-
phoretic and density-gradient behaviour of HDL and LDL
(Woodburn & Kessel, 1994). These results suggest that the
use of Cremophor for Taxol formulation can be an impor-
tant factor in drug biodistribution. We therefore eamine
the effects of 24 h Taxol infusions on serm lipoprotein
profiles and on drug affinity for different serum components
in vivo and in vitro.
Materal ami mthoi
Cremophor was provided by Sigma (St Louis, MO, USA).
[13-3H]Taxol (l.66)Cimmol-') was obtained from the
Research Triangle Institute; radiochemical purity was 99% in
two high-performance liquid chromatographic (HPLC)
systems. Patients entered in this study received
120-150mgm 2 Taxol by intravenous infusion over a 24h
period. At specified times before, during or after this
infusion, blood samples were coleted and the resulting sera
stored for 1-3 days at 4-C in the presence of 1 mM EDTA It
is important that this time interval not be exceeded, since the
lipoprotein dissociation products gradually disappear during
storage, although the gel pattern is not restored to the
4pretreatment' result.
Lipoproteins
To provide standards for lipoprotein dissociation studies,
LDL and HDL were isolated from pooled normal sera by
sequential ultracentrifugation (Schumaker & Puppione,
1986). These products were stored in 1 mM EDTA, under
nitrogen, at 4C.
Density-gradient ultracentrifugation
Effects of Cremophor on the buoyant density of HDL and
LDL were delineated by density-gradient ultracentifiugation
(Sykes et al., 1992) with minor modifications. Serum samples
(250p1) were brought to a volume of 750i1 with isotonic
sodium chloride and the density adjusted to 1.21 g ml-' by
addition of solid potassium bromide. These preparations
were layered over 750p1l of a potassium bromide solution
(density = 1.27 gml-') in 13 x 38 mm polyallomer centrifuge
tubes, and the tubes filled with isotonic saline (total
volume = 3.9 ml). The tubes were spun for 60min at
100,000 r.p.m. (r1, = 254,000g) in a Beckman TL-100 table-
top ultracentrifuge using a TLN rotor. The tubes were frac-
tionated from the top, using a Harvard syringe pump to
inject a dense solution (Fluornert FC-40, ISCO, Lincoln,
NE, USA) into the bottom of the tubes at 0.5mlmin-'.
Twenty-five equal fractions were collected using an ISCO 560
fractionator.
Drug-binding studies
To examine the affinity of radioactive Taxol for albumin and
lipoproteins, sera (250i1) from normal controls or Taxol-
treated patients were mixed with radioactive Taxol (0.1 jg,
5 x 10' c.p.m.) and incubated for 10 min at 3rC. After ult-
racentrifugation, the Taxol klvel in the different fractions was
deterTmined by liquid scintillation counting. To assess effects
of Cremophor on Taxol binding in vitro, control sera were
incubated with Cremophor (0.16 or 0.32%, v/v) for 10 min at
37C before addition of the radioactive Taxol. Serum
albumin and lipoprotein components were then separated by
density-gradient ultracentrifugtion, and binding of Taxol to
these fractions was assessed by liquid scintillation counting.
When mesoporphyrin was used as a fluorescent label for
protein and lipid, fluorescence was detected after bringing
eluted fractions to a total volume of 3 ml with 10 mM Triton
X-100 de nt Fluorescence was measured at 620-650 nm,
using 400 nm excitation.
Gel electrophoresis
Sera from Taxol-treated patients were also analysed by
agarose gel electrophoresis (Paragon system, Beckman
Instruments). The effects of incubation for 10min at 37C
with 0.04, 0.08 and 0.16% (v/v) Cremophor on purified LDL
and HDL were also determined. Sudan black staining was
used to identify lipoproteins on the gels, Coomassie blue to
identify proteins.
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Gel-exclusion chromatography
To provide additional information on the lipoprotein dis-
sociation products, ['4Cjsucrose was covalently bound to the
protein moieties of human LDL and HDL (Pittman et al.,
1979). In other experiments, both protein and lipid com-
ponents of these lipoproteins were labelled with the fluores-
cent probe mesoporphyrin (Woodburn & Kessel, 1994). After
incubation of the purified lipoproteins with Cremophor as
described above, the modified lipoproteins were analysed on
a I x 15 cm Bio-Rad A_5M gel-exclusion column and eluted
with 50 mM phosphate buffer pH 7.2 containing 1 mm
EDTA. Both radioactivity and fluoresnce of the eluted
fractions were monitored. Measurement of phospho}ipids in
these fractions were carried out as described by Warnick
(1986).
Res
Gel electrophoresis analysis
The history of serum samples obtained from patients receiv-
ing Taxol therapy is outlined in Table I. An elctrophoretic
examination of these sera indicated a marked alteration in
lipid profiles during Taxol administration (Figure 1), with
decreased ekctrophoretic mobility of the individual lipo-
proteins, along with the appearance of new electropositive
bands which migrated toward the cathode. In individual
patients, this altered pattern was detectable over the course
of the 24 h drug infusions (lanes 3, 5 and 7) and for
0.5-1.5h afterwards (lane I and 9).
Treatment of purified human HDL or LDL with Cremo-
phor resulted in imilar decreases in the eectrophoretic
mobility (Figure 2) along with the appearance of new bands
that stained with Sudan black and migrated slightly toward
the cathode. These effects were dose dependent. The lack of
staining of these bands with Coomassie blue (Figure 3),
indicates a very low protein content.
Storage of these samples for 2 months at 4 C sometimes
resulted in a loss of the new bands, with the appearance of
additional bands below and above the LDL fraction. There
can be multiple determinants of such behaviour, so we
Table I
Drug
Lne Patient Description (mgm2)
C Control
I SC 1.5 h after end ofinfusion 150
2 SC 6days later
3 MK I h after beginning infusion 135
4 MK 23 days later
5 MK 0.5 h after beginning second infusion 135
6 SG 1 h before ning infusion
7 SG 23.5 h after beginning infusion 135
8 HL 1 h before ning infusion
9 HL 0.5 h after end ofinfusion 120
Source of serm samples shown in Figure 3.
limited all studies reported here to freshly obtained serum
samples.
Density-gradient separations
Using density-gradient ultracentrifugation, we analysed the
binding of radioactive Taxol to serum protein and lipo-
proteins and the effects ofCremophor on this distribution. In
normal pooled serum (Figure 4, top), Taxol was preferen-
tially bound to albumin (centred at fraction 23) and HDL
(fractions 17 and 18); some binding to LDL (fraction 6) was
also observed. Addition of 0.16% Cremophor caused a per-
turbation of this pattern, with radioactivity shifted to frac-
tions with a lower bouyant density. When gradient fractions
4-7 from a preparation of sera + 0.16% Cremophor were
dialysed, concentrated and analysed by gel electrophoresis,
the products present migrated toward the cathode, and were
stained by Sudan black but not by Coomassie blue.
Taxol binding
Binding of radioactive Taxol to serum from a patient (M.K.)
before and during drug administration was also examined
(Figure 4, bottom). The 'pretreatment' sample (Figure 3),
lane 4) showed a drug-binding pattern (0) similar to the
result obtained with the normal pooled serum control. In
contrast, binding of Taxol to the serum sample obtained
during the drug infusion (Figure 3, lane 5) showed a different
pattern (A), with substantial Taxol binding to fractions 1-8.
Concentration of these fractions followed by gel electro-
phoresis revealed the presence of an anodic band which
stained with Sudan black but not with Coomassie blue.
Flge 2 Efects of graded lees of Cremophor, specified as
v/v (%), on HDL and LDL. Lanes 1-4, HDL: lane 1, control
HDL; lane 2, 0.04%; lane 3, 0.08%; lane 4, 0.16%; lane 5,
control LDL; lane 6, 0.04%; lane 7, 0.08%; lane 8, 0.16%. In
these gels, the sample application point is indicated by the letter
'C'. Gels were stained with Sudan black.
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Fugwe I Effect of Taxol administraon on lipoprotein electro-
phoretic patterns (see Table I for details). These gels were stained
with Sudan black.
Figwe 3 Lanes 1-4, Sudan black stain; lanes 5-8, Coomassie
blue stain. Lanes I and 5, control LDL lanes 2 and 6,
Cremophor-treated LDL (0.16% v/v); lanes 3 and 7, control
HDL; lanes 4 and 8, Cremophor-treated HDL (0.16% v/v).
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Fugw 4 Binding of radioactive Taxol in vitro to albumin and
lipoprotein compoents of human serum separated by density-
gradient ultracentrifugtion. Top: Normal control serum (0) and
serum + 0.16% Cremophor (A). Bottom, serum from patient
M.K. before (0) and I h after the beginning (A) of a Taxol
infusion.
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Fge 5 Gel elution prc>file ofnative human LDL labdkd with
["Crxose and a fluorescent probe (mesoporphyrin), then
incubated with CRM (0.16% v/vr) and fractionated on a BioRad
A,_5M cohimn as decibed in the text. The soEdline bwmresents
radioactrity, the dotted line fluorecnce. The locations of LDL
and phospholipid components (as kidentified by analytical pmoo-
dures) are indicated.
'ioprotein &sFociationproducts
ro provide additional information on effects of Cremophor
)n lipoproten, we examinedi the effects of Cremophor on
IDL and HDL with tple apofpoprotian labelled with sucrose
Pittman et al., 1979). We also used the fluorescet probe
nesoporphyrin to label both lipid and protan c omponents of
ipoproteins (Woodburn & Kessel, 1994). When sucrose
labelled HDL or LDL was eluted through this column, we
observed a sharp peak of both fluorescence and radioactivity
centred at fraction 27 (not shown). When Cremophor was
present (0.16% Cremophor, v/v), the elution profile of
sucrose-labelled lipoprotein was unchanged, but the pattern
of mesoporphyrin labelling was altered, with a substantial
amount of fluores appearing in later fractions (35-50).
Data obtained with LDL + CRM are shown in Figure 5.
Analysis of these fractions by gel electrophoresis indicated
that the fraction labelled with '4C migrated slightly slower
than native LDL, while the material in fractions 35-45
migrated toward the cathode, and was stained with Sudan
black but not with Coomassie blue.
The electrophoretic analysis shown in Figure 1 indicates a
substantial alteration in serum lipoprotein profiks durng the
course of a 24 h infusion of Taxol formulated with Cremo-
phor. Data shown in Figure 4 indicate that Taxol has a
strong aflinity for the dissociation product(s), represented by
fractions 1-8, which are produced by the action of Cremo-
phor on native lipoproteins. Since the lipoprotein perturba-
tion induced by Cremophor persists over the duration of the
drug infusion, and for at kast 1.5 h thereafter, the use of
Cremophor as a vehicle for Taxol formulation may affect
drug biodistribution patterns to the extent that these are
influenced by the affinity of the Taxol-phospholipid complex
for different issues.
Since all clinical formulations of Taxol involve the use of
Cremophor, we cannot yet evaluate the role of the drug
solubilisation vehicle on drug efficacy. The affinity of the
drug for the lipoprotein dissociation product may promote
biodistribution to neoplastic loci. In the tumour-bearing
mouse, Cremophor, but not Tween-80, promoted lipoprotein
dissociation at concentrations needed for Taxol formulation,
and enhanced persistence of a hydrophobic drug formulated
with Cremophor (Woodburn et al., 1994). The Cremophor
formulation also resulted in an increased persistence ofTaxol
in mouse plasma (unpublished observations).
An additional consideration is the ability ofCremophor to
reverse multidrug resistance by inactivating the multidrug
transporter, which otherwise serves to limit accumulation of
many natural products (Friche et al., 1990; Schuurhuis et al.,
1990; Woodcock et al., 1990). Serum levels of Cremophor
achieved during 24h Taxol infusions were suffiient to re-
verse Taxol resistnce in cell culture (Chervinsky et al., 1993;
Webster et al., 1993). The choice of Cremophor as a drug
delivery vehicle clearly has several unforeseen, but apparently
important, implications with regard to Taxol pharmacology.
Some clnical protocols now call for the use of 3 h Taxol
infilsions which use the same total Cremophor concentration
as was used for the 24 h procedures. This should result in a
higher peak plasma level of Cremophor, and may further
promote lipoprotein dissociation and enhance Taxol respon-
siveness.
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